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ABSTRACT: Antimicrobial resistance has become a major global concern. Development of
novel antimicrobial agents for the treatment of infections caused by multidrug resistant (MDR)
pathogens is an urgent priority. Pyrrolobenzodiazepines (PBDs) are a promising class of
antibacterial agents initially discovered and isolated from natural sources. Recently, C8-linked
PBD biaryl conjugates have been shown to be active against some MDR Gram-positive strains.
To explore the role of building block orientations on antibacterial activity and obtain structure
activity relationship (SAR) information, four novel structures were synthesized in which the
building blocks of previously reported compounds were inverted, and their antibacterial activity was studied. The compounds
showed minimum inhibitory concentrations (MICs) in the range of 0.125−32 μg/mL against MDR Gram-positive strains with a
bactericidal mode of action. The results showed that a single inversion of amide bonds reduces the activity while the double
inversion restores the activity against MDR pathogens. All inverted compounds did not stabilize DNA and lacked eukaryotic
toxicity. The compounds inhibit DNA gyrase in vitro, and the most potent compound was equally active against both wild-type
and mutant DNA gyrase in a biochemical assay. The observed activity of the compounds against methicillin resistant S. aureus
(MRSA) strains with equivalent gyrase mutations is consistent with gyrase inhibition being the mechanism of action in vivo,
although this has not been deﬁnitively conﬁrmed in whole cells. This conclusion is supported by a molecular modeling study
showing interaction of the compounds with wild-type and mutant gyrases. This study provides important SAR information about
this new class of antibacterial agents.
KEYWORDS: antimicrobial resistance, medicinal chemistry optimization, minimum inhibitory concentration, pyrrolobenzodiazepine,
ESKAPE pathogens
The resistance of pathogens to antibacterial agents hasbecome a major global concern. Multidrug resistant
(MDR) bacteria cause many common and severe infections for
which treatment is increasingly becoming diﬃcult or in some
cases impossible.1 The spread of healthcare-associated
infections and associated antimicrobial resistance is facilitated
by interspecies gene transmission, poor sanitation, and hygienic
conditions, along with the increasing frequency of global travel,
trade, and disease transmission.2 Of great concern among all
the bacteria that are developing resistance is a group of
pathogens termed the ESKAPE pathogens,3 which are
characterized by the rapid acquisition of resistance to multiple
classes of antibiotic (with resistance to 3 or more classes
referred to as multidrug resistance). These species are primarily
associated with nosocomial infections especially among
immunocompromised patients,4 and this also has an additional
economic impact upon the healthcare system.1,5 Although the
measurement of additional costs is complicated,6 the estimated
economic impact for the U.S. economy is reported to be higher
than $20 billion in direct annual healthcare costs.7
In the last 30 years, no major classes of broad spectrum
antibiotics have been introduced to the market, and recently
approved agents like linezolid (2000), daptomycin (2003), and
retapamutilin (2007) are active only against Gram-positive
pathogens.8 A recent report from the World Health
Organization has highlighted the limited number of drugs in
the pipeline with only a few molecules in phase 2 and 3 of
clinical development against ESKAPE pathogens; these are
predominantly focused on Gram-positive species or are
iterations of existing drugs (notably β-lactamase inhibitor
combinations). This highlights the need to identify and evaluate
new therapeutic options and/or to modify existing chemical
scaﬀolds to obtain antibiotics with improved properties,10 and a
number of agents developed through this approach are
currently undergoing clinical trials.9
Applying the same principle, we selected the pyrrolobenzo-
diazepines (PBDs) as a relatively unexplored chemical scaﬀold
to generate new antibacterial compounds with improved
bioactivity and elucidate the structure activity relationship
(SAR) of C8-linked PBDs. PBDs are naturally occurring
molecules produced by Streptomyces bacteria whose family
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members include anthramycin and tomaymycin.11,12 PBDs are
a class of sequence-speciﬁc DNA minor groove binding agents
that are selective for GC-rich sequences, which have been
evaluated as potential chemotherapeutic agents in recent
years.13 PBDs have a chiral center at their C11a(S)-position
which provides an appropriate 3D shape for them to ﬁt securely
within the DNA minor-groove. They also possess a “soft”
electrophilic imine moiety at their N10−C11 position which
can form an aminal linkage between their C11-position and the
C2−NH2 group of a guanine base only when the molecule is
secure within the minor groove.14,15 Anthramycin was the ﬁrst
naturally derived PBD, initially discovered and isolated in 1963
from Streptomyces and Micrococci bacteria,16 and later many
other natural and synthetic PDBs followed. Naturally occurring
PBDs such as anthramycin, tomaymycin, neothramycin, and
sibiromycin form adducts that span three base pairs, with
guanine in the central position,17,18 and their preferred binding
site is 5′-AGA-3′,19 although more recent data suggest that they
have a kinetic preference for 5′-Py-G-Py-3′ sequences.20 PBD
monomers can recognize and bind to speciﬁc sequences of
DNA and therefore have the potential to act as competitive
inhibitors of transcription factors. Considering their mechanism
of action, PBDs have been extensively studied as anticancer
agents but relatively unexplored as antibacterial agents.21−24
Diﬀerent studies showed the possibility of synthesizing PBD
analogues characterized by their high selectivity for particular
DNA sequences, by modifying the C8 position substituent.25,26
For example, PBD−biaryl conjugates, a subclass of monomers
with C8-subunits, have shown preferences for GC sequences.27
Molecules belonging to this subclass have been demonstrated
to be well tolerated in mice at high concentrations, and
molecular dynamics simulations indicate that they are easily
accommodated within the minor groove causing little distortion
to the DNA structure.
We previously studied numerous PBD−biaryl conjugated
structures and identiﬁed some characteristics that are important
for optimal antibacterial activity against Gram-positive
pathogens.24 Among the compounds studied, we selected two
compounds which showed excellent antibacterial activity
against MDR Gram-positive pathogens (minimum inhibitory
concentration (MIC) range: 0.003−0.125 μg/mL) for our
investigation. The ﬁrst compound is a PBD-Py-Bzf (Py =
pyrrole, Bzf = benzofuran) conjugate, while the second
structure was a PBD-Py-Bzt (Bzt = benzothiophene) (Figure
1) conjugate. Starting from these two molecules, we designed
four new molecules with a diﬀerent orientation of the building
blocks constituting the C8 lateral chain. It has been reported in
the literature that the standard orientation of the amide bonds
provide additional hydrogen bond contact with the minor
groove of DNA, and inversion of the amide linkage should
result in loss of these contacts and reduced binding to
DNA.23,25 There is a positive correlation between DNA binding
and eukaryotic toxicity of PBD monomers, and a reduction in
binding should result in reduction or loss of toxicity. First, we
wanted to investigate the antibacterial activity of the derivatives
characterized by the inversion of the amide linkage between N-
methylpyrrole and the alkyl spacer and later the derivatives with
both the reverse N-methylpyrrole and the amide bonds
between the building blocks (Figure 2) and obtain compounds
with reduced eukaryotic toxicity. To achieve the synthesis of
these new PBD-C8-benzofused conjugates, we needed a new
PBD core with a 4C−NH2 linker in place of traditional 4C−
COOH linker. Tiberghien et al. reported the use of this
functionality in 200828 for the synthesis of PBD dimers, but in
this work, for the ﬁrst time, it was used for the synthesis of C8-
linked PBD monomers; the synthesized compounds are the
ﬁrst examples of C8-linked PBD monomers with an inverted
amide linkage between the 4C-spacer and the heterocyclic
building blocks. Moreover, from a synthetic chemistry point of
view, this modiﬁcation allowed us to avoid the protection of the
hydroxyl group at C11, otherwise necessary to prevent the
racemization of (S) C11a observed in the previous synthesis
during the basic methyl ester hydrolysis employed in C8-PBD
monomer synthesis.23
The newly synthesized compounds were tested against
susceptible and MDR Gram-positive bacterial strains. The
Figure 1. Structure of KMR-28-31 (27, PBD-Py-Bzf) and KMR-28-32 (30, PBD-Py-Bzt), previously reported C8-benzofused PBDs with
antistaphylococcal activity (MIC ≤ 0.125 μg/mL).
Figure 2. (A, B) Structures showing (in brackets) the reverse moieties and (in red) the diﬀerent building blocks from the reference compounds. (C)
Traditional PBD core with 4C-acid linker. (D) New PBD core with 4C-amine linker.
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compounds were also tested in a ﬂuorescence resonance energy
transfer (FRET) based DNA melting assay, to evaluate the
eﬀect of inverse orientation on the DNA binding ability of the
compounds, and against mammalian cell lines to assess their
selectivity for prokaryotic cells. The mechanisms of action of
the compounds were studied initially by an in silico screening
against bacterial targets, followed by a biochemical assay against
the wild-type and mutant target identiﬁed by the in silico study.
Finally, molecular modeling experiments were performed to
rationalize the obtained biological results.
■ RESULTS AND DISCUSSION
Chemistry. Both the synthetic strategies followed for the
synthesis of the core bearing the 4C−COOH (Scheme 1) and
the core bearing 4C−NH2 functionality are based on the
previously reported Thurston/Rahman approach.23 The PBD
core used to synthesize the ﬁnal compounds with standard
orientation was obtained as Alloc-THP-protected PBD unit
(9). Brieﬂy, vanillin was alkylated with methyl 4-bromobutyrate
employing K2CO3 in DMF providing the ester derivative 1 after
precipitation. Subsequently, 1 underwent a selective nitration
reaction using KNO3/TFA to give 2 in good yield after an
aqueous workup. The nitrobenzaldehyde derivative 2 was then
oxidized to the carboxylic acid intermediate 3 using KMnO4.
The key intermediate 4 was obtained by amide coupling
between 3, which had been activated to the corresponding acid
chloride by treatment with oxalyl chloride, and optically pure
(S)-pyrrolidine methanol. Reduction of the nitro derivative 4 to
the corresponding amino derivative 5 was accomplished with
Pd/C in a Parr hydrogenator system at 40 psi, followed by
Alloc protection giving 6 in good yield after puriﬁcation by
column chromatography. The Alloc-protected PBD ring system
Scheme 1. Synthesis of PBD Acid Core 9
Scheme 2. Synthesis of PDB Amino Core 18
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7 was then obtained by oxidative cyclization using the BAIB/
TEMPO oxidizing system. In order to prevent racemization at
the C11a position of the PBD ring system, which occurs under
alkaline conditions, the alcohol derivative 7 was protected with
a THP ether giving 8. The ﬁnal Alloc-THP-protected PBD
capping unit 9 was obtained via hydrolysis of the methyl ester
using 0.5 M NaOH aqueous solution.
The synthetic strategy to obtain the C8-linked PBDs with
inverted amide bonds (Scheme 2) involved protection of the
reactive amino group on the 4C-spacer to avoid side reactions,
and the reaction steps were adjusted to take this modiﬁcation
into account. Particularly, acidic conditions were avoided after
the introduction of the Boc-protected amine side chain. To
obtain the type 2 core, vanillin was coupled with benzyl
bromide under alkaline condition giving the ether derivative 10
after recrystallization. This additional step allowed the selective
nitration that led to 11 with a good yield. The benzyl group was
then removed with concentrated HBr in acetic acid to aﬀord
the nitro-vanillin derivate 12. The amide coupling reaction with
(S)-pyrrolidine methanol to obtain 15 was performed using 2-
(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuoro-
phosphate (HBTU) and N,N-diisopropylethylamine (DIPEA)
rather than oxalyl chloride to avoid the generation of acid. The
ﬁnal Alloc-protected PBD capping unit was obtained via the
deprotection of the amino group by TFA in DCM, just before
the coupling with the selected tail.
The synthesis of the C8-side chains was achieved by amide
coupling between the selected building blocks (Scheme 3). An
EDCI/DMAP reagents system was used for the activation of
the acid, leading to intermediate 19 to 24 with variable yield
(20% to 93%). Nitrile groups of 20 and 23 were hydrolyzed by
reﬂuxing in dioxane in a strongly acidic environment (with the
presence of H2SO4) to give 25 and 26 after puriﬁcation by
column chromatography.
The last step in the synthesis of the C8-linked benzofused-N-
methylpyrrole PBD derivatives consisted of several sequential
passages. At ﬁrst, when it was necessary, the capping units were
deprotected. Methyl esters of derivatives 21 and 24 were
hydrolyzed under basic conditions (in a NaOH aqueous
solution), leading to the acid compounds, while the amino
groups on 19 and 22 were deprotected in an acidic
environment (TFA in DCM). Subsequently, the PBD core
and the benzofused-N-methylpyrrole tails were connected
through an amide coupling reaction. Once again, the EDCI/
DMAP system was used to carry out acid activation and
coupling. Finally, the conjugated products were deprotected
with pyrrolidine and Pd(PPh3)4 in DCM, aﬀording the ﬁnal
compounds 27, 28, 29, 30, 31, and 32 (Scheme 4). The ﬁnal
deprotection was common to all the products regardless of the
presence of THP protection, and both the protected and the
ﬁnal PBD imine conjugates were puriﬁed by column
chromatography.
Evaluation of DNA Binding Ability of the Synthesized
Compounds. The ability of compounds 27, 28, 29, 30, 31,
and 32 to bind and stabilize the DNA was evaluated using a
FRET based DNA melting assay29 to understand the eﬀect of
building block orientation on the DNA binding ability of the
compounds. The compounds were tested using two ﬂuoro-
phore-labeled oligonucleotide sequences (Sequence F1: 5′-
FAM-TAT-ATA-TAG-ATA-TTT-TTT-TAT-CTA-TAT-ATA-
3′-TAMRA and Sequence-F2: 5′-FAM-TAT-AGA-TAT-AGA-
TAT-TTT-ATA-TCT-ATA-TCT-ATA-3′-TAMRA, where
FAM is 6-carboxyﬂuorescein and TAMRA is 5-carboxytetra-
methylrhodamine). Netropsin, a known DNA minor groove
binder, was used as a positive control. The result of the assay is
reported in Table 1. Previously reported C8-PBD conjugates 27
and 30 and control compound netropsin showed notable
stabilization of both DNA sequences at 1 μM, but the C8-PBD
compounds with inverted building blocks, 28, 29, 31, and 32
did not stabilize the DNA sequence, with ΔTm values <1 °C at
1 μM concentration (drug/DNA ratio 5:1). The result suggests
the inversion of single or both amide bonds reduced the ability
of these compounds to interact with and stabilize the DNA
sequences.
Evaluation of Eukaryotic Toxicity. The inability of the
inverted C8-PBD conjugates to stabilize DNA sequences
suggested the compounds may show reduced toxicity against
eukaryotic cell lines, as DNA stabilization has been associated
with cytotoxicity for PBD-type covalent minor groove bind-
ers.30 The eukaryotic cytotoxicity of the synthesized com-
pounds was tested against the cervical cancer cell line HeLa and
the nontumor lung ﬁbroblast WI38 using an MTT assay.31 The
original C8-PBD benzofused conjugates 27 and 30 showed very
potent cytotoxicity against the HeLa cell line (Figure 3) with
only 25% and 32% cells viable after 24 h. The compounds
showed slightly less toxicity against the nontumor cell line WI
38 with 42% and 47% cells viable after 24 h. However, the
inverted compounds 28, 29, 31, and 32 showed notably less
toxicity against both HeLa and WI38 cell lines. In the case of
the inverted compounds, >70% of cells were viable after 24 h of
treatment with the molecules. This lack of toxicity was in line
with the DNA binding ability of the compounds, and this is
consistent with previous reports that PBDs exert their
cytotoxicity by alkylating and stabilizing DNA sequences.32
Microbiological Evaluation. The inverted amide com-
pounds and the parent compounds were tested against a
selected panel of Gram-positive bacteria to assess their
antibacterial activity (Table 2). The Gram-positive panel was
comprised of Staphylococcus aureus and Enterococcus spp. strains,
which comprise the “S” and the “E” from the ESKAPE
pathogens acronym. The strains used were methicillin sensitive
S. aureus (MSSA) strain ATCC 9144, two methicillin resistant
S. aureus (MRSA) strains, EMRSA-15 (strain HO 5096 0412)
and EMRSA-16 (strain MRSA 252), vancomycin sensitive
Scheme 3. Generic Amide Coupling Reactions in the
Synthesis of Benzofused-N-Methylpyrrole Intermediates
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E. faecalis (VSE), strain NCTC 755, vancomycin resistant
E. faecalis (VRE, vancomycin resistant Enterococci), strain
NCTC 12201, and vancomycin resistant E. faecium (VRE),
strain NCTC 12204. As expected, compound 27 showed good
antibacterial activity with MICs lower than 0.125 μg/mL
against all Gram-positive strains tested. Surprisingly, the
inversion of one amide linkage in compound 28 resulted in a
considerable loss of activity with an MIC of 2 μg/mL against
VRE strains and 16 μg/mL against VSE and MSSA strains. The
drop in activity was particularly surprising against MRSA
strains, with an MIC higher than 32 μg/mL. Interestingly,
compound 29, characterized by the inversion of both the amide
linkages and the N-methylpyrrole building block, presented a
better antibacterial proﬁle than 28. Although it was found to be
less potent than 27, compound 29 maintained moderate
activity against the bacterial strains with MICs between 0.5 and
4 μg/mL. The observations made for the benzofuran series of
C8-PBD conjugates were further conﬁrmed by evaluating the
C8-benzothiophene series of inverted and parent PBD
compounds (Table 2). Compound 32 showed antibacterial
Scheme 4. Synthesis of Standard and Inverted Orientation Benzofused-N-Methylpyrrole PBD Derivatives
Table 1. DNA Duplex Stabilization for Natural and Inverted
C8-PBD Compoundsa
ΔTm at 1 μM
compounds sequence F1 sequence F2
27 20.8 ± 0.2 9.5 ± 0.5
28 0.0 ± 0.2 0.4 ± 0.1
29 0.1 ± 0.1 0.5 ± 0.3
30 21.7 ± 0.2 11.1 ± 0.9
31 0.2 ± 0.1 0.5 ± 0.1
32 0.4 ± 0.1 0.9 ± 0.1
netropsin 13.8 ± 0.3 11.0 ± 0.2
ciproﬂoxacin 0.0 ± 0.4 0.2 ± 0.3
aΔTm values are reported in the table in C° in comparison to the
control. Assay conducted in triplicate.
Figure 3. Eukaryotic toxicity of the C8-benzofused PBDs with natural and inverted building blocks at 25 μM after 24 h of incubation against (A)
cervical cancer cell line HeLa and (B) nontumor lung ﬁbroblast WI38.
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activity comparable to previously reported compound 30
against Enterococci strains with MICs lower than 0.125 μg/
mL. However, a drop in activity was observed against S. aureus
strains with MICs higher than 32 μg/mL against MRSA and of
16 μg/mL against MSSA. Compound 31 showed antibacterial
activity similar to 32 against S. aureus strains but generally
Table 2. Minimum Inhibitory Concentrations of C8-PBD Benzofused Analogues with Natural and Inverted Building Blocks
against Gram-Positive Strains and IC50s, Against Eukaryotic Cells
Gram-positive strains MIC (μg/mL)
VRE VSE MRSA MSSA IC50 (μg/mL)
compound NCTC 12201 NCTC 12204 NCTC 775 EMRSA 15 EMRSA 16 ATCC 9144 WI38 HeLa
27 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.125 0.14 0.03
28 2 2 16 >32 >32 16 >28.4 >28.4
29 0.5 1 4 2 4 2 >28.4 >28.4
30 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.125 ≤0.125 0.07 0.03
31 2−4 ≤0.125 1 >32 >32 16 >28.4 >28.4
32 ≤0.125 ≤0.125 ≤0.125 >32 >32 16 >28.4 >28.4
Cipro 0.5 2 1 32 32 ≤0.125 >28.4 >28.4
Figure 4. Response of EMRSA-15 and VRE-12201 strains to treatment with suprainhibitory concentrations (4× MIC) of compound 29.
Figure 5. Covalent interactions between a random sequence of DNA and compounds 27 (A), 28 (B), and 29 (C) in the top panel and 30 (D), 31
(E), and 32 (F) in the lower panel. All compounds lay along the minor groove of DNA and form covalent interaction to the exocyclic N2 atom of
NH2 group of a guanine (in yellow sticks) with their C11 atom present in the CN imine bond.
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showed higher MICs against other strains. Overall, the inverted
C8-linked benzothiophene PBD compounds showed better
antibacterial activity against Enterococcus strains compared to
the benzofuran compounds, while among the four newly
synthesized compounds, the inverted benzofuran derivative 29
was found to be most active against S. aureus strains.
The mode of action of compound 29 was explored using
time-kill assays. One MRSA (EMRSA-15) and one VRE
(NCTC 12201) strain were treated with compound 29 at 4 ×
MIC for 24 h, and cell counts were elucidated at speciﬁed time
points. The results show a rapidly bactericidal mode of action in
both strains for compound 29, with cell counts falling below the
limit of detection within 2 h, while the control antibiotic
ciproﬂoxacin displayed a bacteriostatic mode of action (Figure
4). Although a small population of cells was detected after 24 h
of treatment with compound 29 in EMRSA-15 (in two of three
replicate experiments), no resistance to the compound was
detected in this population (assessed by determining the MIC
of surviving cells), and as such, they most likely represent a
persistor population. This is observed in EMRSA15 (ﬂuo-
roquinolone resistant) but not in strain NCTC12201
(ﬂuoroquinolone sensitive), although the role of ﬂuoroquino-
lone resistance in persistor survival in these assays is unproven.
In Silico DNA Interaction Study. In order to rationalize the
obtained results, a molecular modeling study was carried out
using three random sequences of DNA: AT-rich Seq-1 (5′-
TATATAAGATATATATA-3′), GC-rich Seq-2 (5′-TAGC-
TAGCTAGCTAGCG-3′), and mixed AT/GC Seq-3 (5′-
GCGCGCGCGCGGCGCGC-3′). Covalent molecular dock-
ing between the N atom of the NH2 group of guanine and the
C11 atom of the CN imine bond in PBDs showed favorable
complexes with good aﬃnities between PBDs and DNA. As
PBDs are known to work by interacting with the DNA minor
groove, we calculated the relative binding free energy of the
DNA−compound complex (Figure 5) using molecular
dynamics simulations followed by Molecular Mechanics-
Poisson Boltzmann Surface Area (MM-PBSA)/Molecular
Mechanics-Generalized Born Surface Area (MM-GBSA)
calculations (Table 3). These models showed favorable energy
values of ΔGGB and ΔGPB for the reference compounds in all
three sequences while the results for the inverted compounds
(28, 29, 31, and 32) were considerably lower than the parent
compounds 27 and 30. The modeling study supported the lack
of DNA stabilization observed in the FRET melting study and
the lack of eukaryotic toxicity. Overall, a positive correlation
between the free energy of binding and antibacterial activity
was observed suggesting that DNA binding plays a role in the
antibacterial potency of these compounds.
Mechanistic Evaluation. As the inverted C8-analogues did
not stabilize DNA sequences and were nontoxic to eukaryotic
cells, the mechanism of action of these molecules is likely to be
DNA independent. To explore this further, we carried out an in
silico docking campaign with known bacterial targets (ESI) to
get an indication of the mechanism of action of these inverted
pyrrolobenzodiazepines. Among the targets studied, the
inverted compound 29 interacted with the ligand binding
domain of DNA gyrase and showed excellent aﬃnity toward
both subunits of bacterial DNA gyrase. The best pose of
compound 29 with the bacterial gyrase from Staphylococcus
aureus (PDB ID 2XCT) gave a CHEM Score of 21.68 and
aﬃnity of −29 (kcal/mol) for subunit 1 of gyrase A and a
CHEM Score of 23.29 and aﬃnity of −30 (kcal/mol) for
subunit 2 of gyrase A (Figure 6 and Table S2). The 2D models
shown in Figure 6C suggest compound 29 forms three
conventional hydrogen bonds with serine 98, arginine 92, and
glutamine 95 of the subunit 1 of DNA gyrase A. Other key
interactions are reported in Table S4. Similarly, compound 29
also forms three conventional hydrogen bonds with serine 85,
arginine 92, and serine 98 of the subunit 2 of gyrase A (Figure
6D). A number of hydrophobic and electrostatic interactions
with diﬀerent amino acids from subunits of gyrase A were also
observed (Table S5). The interaction of 29 with the ligand
binding site of gyrase A suggests the antimicrobial activity is
due to the inhibition of gyrase A by directly interacting with the
enzyme and not due to its ability to associate with DNA.
The in silico observation was validated by carrying out a DNA
gyrase inhibition assay using a commercial S. aureus gyrase
supercoiling high throughput plate assay (#SATRG01) kit
obtained from Inspiralis (Norwich, UK) (Figures 7 and S4).
Compound 29 inhibited wild-type gyrase isolated from S. aureus
with an IC50 of 0.95 ± 0.30 μg/mL which is signiﬁcantly (P <
0.05) better than ciproﬂoxacin which inhibited the wild-type
gyrase with an IC50 of 2.85 ± 1.80 μg/mL. Surprisingly,
compounds 27 and 30 also showed comparable IC50’s, 1.65 ±
0.68 and 2.28 ± 0.98 μg/mL, respectively, against wild-type
gyrase (Figure 7). There was no statistically signiﬁcant
diﬀerence between the IC50 of compounds 27, 29, and 30.
This data does not provide a clear diﬀerential in gyrase
inhibition between compounds that stabilize DNA (27 and 30)
and may inhibit gyrase, a DNA associated enzyme, and
compounds that have not shown DNA stabilization (29 and
ciproﬂoxacin, Table 1), where we would infer direct inhibition
by gyrase binding. Competition assays were used to try and
deﬁne the basis of the interaction. However, no clear answer
could be obtained, as doubling the concentration of enzyme in
the gyrase assays reduced the inhibition caused by compound
29 and ciproﬂoxacin but not compound 30, which supports our
inference, but a reduction in inhibition was also observed for
compound 27 which could not be explained (Figure S5).
One of the most common mutations found in ﬂuoroquino-
lone resistant S. aureus strains is the S84L mutation in the gyrA
subunit. We tested compound 29 against a gyrase enzyme
Table 3. Energy Values Calculated Using the Poisson
Boltzmann Model and Generalized Born Model and
Expressed as kcal/mol for Each DNA−Compound Complex
complex ΔGGB (kcal/mol) ΔGPB (kcal/mol)
Seq1-27 −39 −40
Seq1-28 −34 −35
Seq1-29 −33 −35
Seq1-30 −42 −43
Seq1-31 −36 −39
Seq1-32 −35 −38
Seq2-27 −38 −39
Seq2-28 −37 −38
Seq2-29 −36 −37
Seq2-30 −42 −43
Seq2-31 −38 −40
Seq2-32 −37 −40
Seq3-27 −41 −43
Seq3-28 −38 −39
Seq3-29 −37 −39
Seq3-30 −43 −45
Seq3-31 −37 −39
Seq3-32 −38 −39
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complex containing this mutation and found that, at 20 μg/mL,
compound 29 inhibited the mutant enzyme by 60.0% ± 11.2%,
while ciproﬂoxacin inhibited the mutant enzyme by just 43.3%
± 1.1% at the higher concentration of 32 μg/mL (Figure S9).
This data suggests that compound 29 retains better activity
against the ﬂuoroquinolone-resistant enzyme than ciproﬂox-
acin. The ability of compound 29 to inhibit the mutated DNA
gyrase led us to carry out a further molecular modeling study to
rationalize the biochemical assay result. The molecular model
of gyrase A with S84L mutation in the gyrA subunit was
developed with PyMol using PDB ID 2XCT as the template.
The structure was minimized, equilibrated, and subsequently
validated by the AMBER package program. Interestingly,
compound 29 interacted with the ligand binding site of mutant
gyrase A (Figure S2) with greater aﬃnity and higher
CHEMSCORE (23.4 for subunit 1 and 23.4 for subunit 2)
compared to the wild-type enzyme. However, ciproﬂoxacin
showed a signiﬁcantly reduced aﬃnity and CHEMSCORE
(15.8 for subunit 1 and 15.9 for subunit 2) for the mutant
enzyme (Figure S3, Table S3), which is consistent with the
literature. Compound 29 formed ﬁve conventional hydrogen
bonds with both subunit 1 and subunit 2 of the mutant enzyme
(Tables S6 and S7). The antibacterial activity observed for
compound 29 against Staphylococcus strains (Table 2) appeared
to support the biochemical assay and the in silico observation as
it showed similar activity (MIC 2−4 μg/mL) against the MSSA
strain ATCC9144, which does not bear the S84L mutation in
gyrase A and the MRSA strains, EMRSA-15 and EMRSA-16,
with the S84L mutation in gyrase A.
■ CONCLUSIONS
This study was focused on understanding how the building
blocks orientation of the lateral C8 side chain of PBDs aﬀect
the antibacterial activity of C8-PBD conjugates and the
suitability of developing C8-linked inverted PBDs as anti-
bacterial agents. Furthermore, we explored the suitability of
using the novel 4C−NH2 linker on the C8-position of the
PBDs, which provides some advantages for the synthesis of the
C8-linked pyrrolobenzodiazepines by avoiding the base
catalyzed hydrolysis step that can result in C11a racemization.
Four inverted C8-linked benzofused PBDs were successfully
synthesized employing both 4C−COOH and 4C−NH2 linkers.
Two of them presented the inversion of the amide linkage
between N-methylpyrrole and the PBD core while the other
two presented the inversion of both amide bonds between the
three moieties constituting the lateral chain and the
Figure 6. (A) Molecular model showing the interaction of compound 29 with the subunit 1 of the S. aureus gyrase A. (B) Molecular model showing
the interaction of compound 29 with the subunit 2 of the S. aureus gyrase A. (C) 2D model showing the key interactions between compound 29 with
the binding site in the subunit 1 of the S. aureus gyrase A. (D) 2D model showing the key interactions between compound 29 with the binding site in
the subunit 2 of the S. aureus gyrase A.
Figure 7. Biochemical analysis showing S. aureus gyrase enzyme
inhibition by compounds 27 (■), 29 (▲), and 30 (▼) and
ciproﬂoxacin (●) which was used as a control.
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heterocyclic building blocks. The single amide bond inverted
compounds showed notably inferior antibacterial activity owing
to their inability to eﬀectively associate with the DNA minor
groove. However, the double inverted compounds showed
comparable activity to the C8-benzofused PBDs with natural
orientation. The inverted C8-analogues did not stabilize DNA
sequences and showed selective toxicity toward prokaryotic
cells. The diﬀerential sensitivity observed between S. aureus and
Enterococcus spp. for compounds 31, 32, and to a lesser extent
28 is intriguing and pointed toward a new mechanism of action
rather than solely DNA-binding, as observed for traditional
DNA minor groove binders. In silico studies followed by
biochemical assays suggested that the compounds are capable
of binding to DNA gyrase and showed inhibition of DNA
gyrase in vitro. The data in this study shows that these
molecules can inhibit both wild-type and mutant DNA gyrase
(S84L mutation in gyrase A) enzymes in vitro and kill S. aureus
strains, carrying this mutation, that are resistant to
ﬂuoroquinolones. The observed IC50 is comparable to
ciproﬂoxacin in the in vitro assay, and this was also the case
for noninverted PBDs (27 and 30). Future studies are required
to re-evaluate the mechanism of bacterial killing by this class of
molecules, both in terms of the kinetics of the in vitro gyrase
inhibition assay and by showing bacterial responses which are
consistent with DNA-gyrase inhibition in vivo. This deeper
understanding of the mechanism of action provides an
opportunity to develop these inverted C8-PBD analogues as
antibacterial agents due to their lack of eukaryotic toxicity and
reasonable activity against MDR Gram-positive pathogens,
potentially reviving PBD based anti-infective research.
■ METHODS
Chemistry. All solvents and reagents for the synthesis were
obtained from commercially available sources, including, among
others, Sigma-Aldrich, Fisher Scientiﬁc, Fluorochem, and Alfa
Aesar. Thin-layer-chromatography (TLC) analysis was per-
formed on silica gel plates (E. Merck silica gel 60 F254 plates)
and visualized by ultraviolet (UV) radiation at 254 nm. Flash
chromatography for the puriﬁcation of compound was
performed with silica gel as a stationary phase (Merck 60,
230−400 mesh). 1H and 13C nuclear magnetic resonance
(NMR) analyses were performed on a Bruker Spectrosp in 400
Hz spectrometer. IR spectra were collected with an FT/IR
IRAﬃnity-1S IR spectrophotometer (Shimadzu). HRMS was
performed on a Thermo Scientiﬁc-Exactive HCD Orbitrap
Mass Spectrometer. LC-MS analyses were performed on a
Waters Alliance 2695 system, eluting in gradient with a ﬂow
rate of 0.5 mL/min using a solvent gradient starting with 5%
acetonitrile that was increased to 95% acetonitrile over a 7.5
min time period (ESI). The analyses were performed on a
Monolithic C18 50 × 4.60 mm column (made by
Phenomenex). UV detection was performed on a diode array
detector. Mass spectra were registered in both the ESI+ and
ESI− mode. The hydrogenation reaction was conducted using
a Parr hydrogenation system. A dynamic light scattering
experiment was performed using a Nanoseries machine
(Malvern Instruments, UK).
Methyl 4-(4-Formyl-2-methoxyphenoxy)butanoate (1).
Methyl 4-bromobutanoate (17.7 mL, 140.2 mmol, 1.05
equiv) and potassium carbonate (30.4 g, 210.3 mmol, 1.5
equiv) were added to a solution of vanillin (20.0 g, 131.4 mmol,
0.9 equiv) in DMF (80 mL). The suspension was stirred at
room temperature for 6 h, until TLC showed the completion of
the reaction. At that point, H2O (1 L) was added to the
reaction, causing the formation of a precipitate that was ﬁltered
and collected giving pure 1 (32.0 g, 95%) as a white solid
(melting point (mp) 65 °C).
Rf value (100% DCM): 0.62;
1H NMR (400 MHz, CDCl3) δ
9.84 (1H, s), 7.40−7.44 (2H, m), 6.98 (1H, d, J = 8 Hz), 4.16
(2H, t, J = 6.2 Hz), 3.92 (3H, s), 3.69 (3H, s), 2.56 (2H, t, J =
7.2 Hz), 2.17−2.23 (2H, m). 13C NMR (100 MHz, CDCl3) δ
190.9, 173.4, 153.8, 149.9, 130.3, 126.8, 111.5, 109.2, 67.8, 56.4,
51.7, 30.3, 24.2. m/z (+ESI) calc. for C13H16O5 (M)
+ 252.2,
found 253.1 ([M] + H)+.
Methyl 4-(4-Formyl-2-methoxy-5-nitrophenoxy)-
butanoate (2). A solution of 1 (10.0 g, 39.6 mmol, 1.0
equiv) in triﬂuoroacetic acid (12 mL) was added dropwise to a
solution of KNO3 (5.0 g, 49.5 mmol, 1.25 equiv) in
triﬂuoroacetic acid (12 mL) kept at 0 °C under a magnetic
stirrer. After 40 min, TLC and LCMS monitoring showed
completion of the reaction. The reaction mixture was
evaporated under reduced pressure using a rotary evaporator.
The residue was dissolved in EtOAc (50 mL), and the organic
phase was washed with brine (3 × 50 mL). The organic phases
were dried over MgSO4 and concentrated by a rotary
evaporator giving pure 2 (10.7 g, 92%) as an amber oil.
Rf value (100% DCM): 0.72;
1H NMR (400 MHz, CDCl3) δ
10.29 (1H, s), 7.46 (1H, s), 7.11 (1H, s), 4.06 (2H, t, J = 6.2
Hz), 3.85 (3H, s), 3.56 (3H, s), 2.42 (2H, t, J = 7.2 Hz), 2.04−
2.11 (2H, m). 13C NMR (100 MHz, CDCl3) δ 188.5, 172.8,
152.7, 150.9, 143.5, 124.7, 110.5, 108.2, 67.8, 56.4, 51.3, 29.7,
23.2. m/z (+ESI) calc. for C13H15NO7 (M)
+ 297.2, found 298.1
([M] + H)+.
5-Methoxy-4-(4-methoxy-4-oxobutoxy)-2-nitrobenzoic
acid (3). Compound 2 (10.0 g, 33.6 mmol, 1.0 equiv) was
dissolved in acetone (400 mL). A hot solution of 10%
potassium permanganate (275 mL) was added to the solution
of 2 in a ﬂask ﬁtted with a condenser. The reaction mixture was
left under reﬂux until the reaction went to completion
(according to TLC). At that point, the reaction mixture was
cooled down to room temperature. The brown residue formed
was ﬁltered through a Celite patch and washed with 600 mL of
hot H2O. A solution of 16% sodium bisulphite in 1 N HCl (400
mL) was added to the ﬁltrate, and the pH of the solution was
adjusted to 1 using concentrated HCl. This caused the
precipitation of a yellow solid that was ﬁltered, collected, and
dried giving pure 3 (9.0 g, 82%) as a yellow solid (mp 114 °C).
Rf value (EtOAc/MeOH 50:50): 0.4;
1H NMR (400 MHz,
CDCl3) δ 7.38 (1H, s), 7.21 (1H, s), 4.15 (2H, t, J = 5.8 Hz),
3.97 (3H, s), 3.70 (3H, s), 2.56 (2H, t, J = 7.2 Hz), 2.17−2.24
(2H, m). 13C NMR (100 MHz, CDCl3) δ 172.8, 166.0, 151.8,
149.1, 141.2, 121.3, 111.5, 107.2, 68.3, 56.4, 51.3, 29.7, 23.8. m/
z (+ESI) calc. for C13H15NO8 (M)
+ 313.2, found 312.1 ([M] −
H)−.
(S)-Methyl 4-(4-(2-(Hydroxymethyl)pyrrolidine-1-carbon-
yl)-2-methoxy-5-nitrophenoxy)butanoate (4). A solution
was prepared by dissolving 3 (7.9 g, 25.2 mmol, 1.0 equiv) in
dry DCM (50 mL) in a round-bottom ﬂask previously dried in
an oven. Oxalyl chloride (6.5 mL, 75.6 mmol, 3 equiv) and a
catalytic amount of DMF (2−3 drops) were added to the
solution that initiated the reaction. The solution was left under
a magnetic stirrer for 1 h until it ceased the formation of HCl.
Dry toluene (15 mL) was added to the reaction mixture that
was evaporated under reduced pressure in a rotary evaporator
to eliminate the excess of oxalyl chloride. The reaction mixture
was dissolved in dry DCM (50 mL), and the solution was
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dropwise added to a solution of triethylamine (10.5 mL, 75.6
mmol, 3 equiv) and +(S)-pyrrolidinemethanol (3.7 mL, 37.8
mmol, 1.5 equiv) in dry DCM (30 mL) kept at 0 °C under N2
atmosphere. The reaction mixture was then allowed to stir
overnight. After 15 h, TLC showed the completion of the
reaction, and the reaction mixture was extracted using 1 N HCl
(2 × 70 mL) and brine (2 × 70 mL). The combined organic
fractions were dried over MgSO4 and concentrated by the
rotary evaporator to give a yellow oil. The crude was puriﬁed by
column chromatography (mobile phase: from EtOAc, 100, v/v,
to EtOAc/MeOH, 98/2, v/v) aﬀording pure 4 (5.5 g, 55%) as a
pale yellow solid (mp 82 °C).
Rf value (EtOAc/MeOH 90:10): 0.46;
1H NMR (400 MHz,
CDCl3) δ 7.69 (1H, s), 6.79 (1H, s), 4.14 (2H, t, J = 4.4 Hz),
3.96 (3H, s), 3.90 (1H, m), 3.78 (1H, m), 3.69 (3H, s), 3.16
(2H, t, J = 6.8 Hz), 2.55 (2H, t, J = 4.8 Hz), 2.10−2.22 (3 H,
m), 1.70−1.90 (4 H, m). 13C NMR (100 MHz, CDCl3) δ
173.2, 154.8, 148.4, 109.2, 108.4, 68.4, 66.1, 61.5, 56.7, 51.7,
49.5, 30.3, 28.4, 24.4, 24.2. m/z (+ESI) calc. for C18H24N2O8
(M)+ 396.3, found 397.0 ([M] + H)+.
(S)-Methyl 4-(5-Amino-4-(2-(hydroxymethyl)pyrrolidine-1-
carbonyl)-2-methoxyphenoxy)butanoate (5). A catalytic
amount of Pd/C (10% w/w) was added to a solution of 4
(5.5 g, 13 mmol, 1 equiv) in EtOH (100 mL). The reaction
mixture was hydrogenated in a Parr hydrogenator at 40 psi for
4 h until TLC showed the completion of the reaction. At that
point, the reaction was ﬁltered under vacuum through a patch
of Celite. The resulting solution was evaporated using a rotary
evaporator giving pure 5 (4.5 g, 95%) as a dark yellow solid
(mp 46 °C).
Rf value (EtOAc/MeOH 90:10): 0.36;
1H NMR (400 MHz,
CDCl3) δ 6.76 (1H, s), 6.39 (1H, s), 4.39 (1H, bs), 4.03 (2H, t,
J = 4.4 Hz), 3.78 (3H, s), 3.69 (3H, s), 3.62 (1H, m), 3.53 (1H,
m), 2.54 (2H, t, J = 4.8 Hz), 2.15 (3H, m), 1.65−1.87 (4H, m).
13C NMR (100 MHz, CDCl3) δ 172.5, 170.7, 150.3, 140.5,
140.1, 135.0, 112.3, 110.5, 101.2, 66.5, 59.9, 56.3, 52.4, 50.6,
29.4, 27.5, 23.9, 23.4. m/z (+ESI) calc. for C18H26N2O6 (M)
+
366.4, found 367.2 ([M] + H)+.
(S ) -Methy l 4- (5- (A l ly loxycarbonylamino)-4- (2-
( h y d r o x ym e t h y l ) p y r r o l i d i n e - 1 - c a r b o n y l ) - 2 -
methoxyphenoxy)butanoate (6). A solution was prepared by
dissolving 5 (3.3 g, 9 mmol, 1.0 equiv) in dry DCM (40 mL).
Dry pyridine (1.7 mL, 21.1 mmol, 2.3 equiv) and a solution of
allyl chloroformate (0.91 mL, 8.5 mmol, 0.95 equiv) in
anhydrous DCM (30 mL) were sequentially added to this
solution, which was kept at −10 °C under N2 atmosphere. The
reaction mixture was left under a magnetic stirrer at room
temperature for 2 h, until TLC showed the completion of the
reaction. At that point, the reaction mixture was extracted with
a saturated CuSO4 solution (70 mL), saturated aqueous
NaHCO3 (100 mL), and brine (100 mL). The organic phase
was dried over MgSO4 and concentrated under reduced
pressure using a rotary evaporator. The crude of the reaction
was subsequently puriﬁed by column chromatography (mobile
phase: EtOAc, 100%) aﬀording pure 6 (3.6 g, 88%) as a pale
yellow solid (mp 49 °C)
Rf value (DCM/acetone 60:40): 0.51;
1H NMR (400 MHz,
CDCl3) δ 8.72 (1H, bs), 7.77 (1H, s), 6.82 (1H, s), 5.95 (1H,
m), 5.35 (1H, dd, J = 17.2, 1.2 Hz), 5.23 (1H, dd, J = 10.0, 0.8
Hz), 4.63 (2H, dd, J = 5.6, 1.2 Hz), 4.40 (1H, bs), 4.11 (2H, t, J
= 4.4 Hz), 3.82 (3H, s), 3.61 (3H, s), 3.59 (1H, m), 3.50 (1H,
m), 2.54 (2H, t, J = 4.8 Hz), 2.17 (3H, m), 1.72−1.92 (4H, m).
13C NMR (100 MHz, CDCl3) δ 173.4, 170.9, 153.6, 150.5,
144.0, 132.3, 131.9, 118.2, 115.7, 111.6, 105.6, 67.7, 66.6, 65.7,
61.6, 60.4, 56.6, 51.7, 30.7, 28.3, 25.1, 24.3. m/z (+ESI) calc. for
C22H30N2O8 (M)
+ 450.4, found 451.2 ([M] + H)+.
Allyl 11-Hydroxy-7-methoxy-8-(4-methoxy-4-oxobutoxy)-
5-oxo-2,3,11,11a-hexahydro-1H-pyrrolo[2,1-c][1,4]-
benzodiazepine-10(5H)-carboxylate (7). BAIB (3.7 g, 11.6
mmol, 1.2 equiv) and TEMPO (152.0 mg, 1.0 mmol, 0.1 equiv)
were sequentially added to a solution of 6 (4.41 g, 9.7 mmol,
1.0 equiv) in DCM (200 mL). The reaction was left under a
magnetic stirrer for 6 h until TLC showed the completion of
the reaction. At that point, the reaction mixture was
sequentially washed with saturated sodium metabisulphite
(100 mL), saturated aqueous NaHCO3 (2 × 100 mL), and
brine (100 mL). The organic phase was dried over MgSO4 and
concentrated under reduced pressure using a rotary evaporator.
The crude of the reaction was puriﬁed by column
chromatography (mobile phase: EtOAc/hexane, 50/50, v/v)
aﬀording pure 7 (3.3 g, 75%) as a yellow solid (mp 74 °C).
Rf value (DCM/acetone 60:40): 0.51;
1H NMR (400 MHz,
CDCl3) δ 7.22 (1H, s), 6.69 (1H, s), 5.80 (1H, m), 5.62 (1H,
d, J = 4.0 Hz), 5.07 (2H, d, J = 12.0 Hz), 4.61 (1H, dd, J = 13.2,
5.6 Hz), 4.41 (1H, bs), 4.21 (2H, d, J = 12.0 Hz), 3.89 (3H, s),
3.67 (3H, s), 3.49 (1H, t, J = 8.0 Hz), 3.43 (1H, m), 2.48 (2H,
t, J = 7.2 Hz), 2.12 (4H, m), 1.95 (2H, m). 13C NMR (100
MHz, CDCl3) δ 173.4, 167.0, 155.9, 149.9, 148.7, 131.8, 128.3,
126.0, 117.9, 114.2, 110.8, 85.9, 67.9, 66.7, 60.3, 60.1, 56.1,
51.6, 46.3, 30.3, 28.7, 24.2, 23.0, 20.9. m/z (+ESI) calc. for
C22H28N2O8 (M)
+ 448.4, found 449.2 ([M] + H)+.
Allyl 7-Methoxy-8-(4-methoxy-4-oxobutoxy)-5-oxo-11-
(tetrahydro-2H-pyran-2-yloxy)-2,3,11,11a-hexahydro-1H-
pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate (8).
DHP (6.3 mL, 75.0 mmol, 10.0 equiv) was added to a solution
of 7 (3.3 g, 7.5 mmol, 1.0 equiv) in the presence of a catalytic
amount of PTSA (33.0 mg, 0.2 mmol, 0.03 equiv) in EtOAc
(50 mL). The reaction mixture was left under a magnetic stirrer
for 2 h until TLC showed the completion of the reaction. At
that point, the reaction mixture was extracted with saturated
aqueous NaHCO3 (2 × 50 mL) and brine (50 mL). The
organic phase was dried over MgSO4 and evaporated using a
rotary evaporator under reduced pressure. The crude of the
reaction was puriﬁed by column chromatography (mobile
phase: DCM/acetone, 90/10, v/v) aﬀording pure 8 (3.6 g,
85%) as a yellow solid (mp 53 °C).
Rf value (DCM/acetone 60:40): 0.67;
1H NMR (400 MHz,
CDCl3) δ 7.19 (1 H, s), 6.88 (1 H, s), 6.60 (1 H, s), 5.68−5.90
(4 H, m), 5.00−5.20 (8 H, m), 4.30−4.70 (4 H, m), 4.05−4.15
(6 H, m), 3.80−3.92 (8 H, m), 3.62−3.73 (8 H, m), 3.40- 3.55
(8 H, m), 2.50−2.64 (4 H, m), 2.90−2.10 (8H, m), 1.65−1.84
(6 H, m), 1.42−1.62 (15 H, m). 13C NMR (100 MHz, CDCl3)
δ 173.4, 167.4, 149.1, 132.0, 114.9, 100.0, 98.4, 96.1, 94.6, 91.7,
88.6, 68.0, 67.7, 66.5, 63.6, 62.9, 60.1, 56.1, 51.6, 51.2, 46.3,
30.9, 30.2, 29.0, 25.4, 24.2, 20.0. m/z (+ESI) calc. for
C27H36N2O9 (M)
+ 532.5, found 533.2 ([M] + H)+.
4-(10-(Allyloxycarbonyl)-7-methoxy-5-oxo-11-(tetrahy-
dro-2H-pyran-2-yloxy)-2,3,5,10,11,11a-hexahydro-1H-
pyrrolo[2,1-c][1,4]benzodiazepine-8-yloxy)butanoic acid (9).
An excess of NaOH 1 M aqueous solution was added to a
solution of 8 (3.8 g, 7.1 mmol, 1.0 equiv) in MeOH (60 mL).
The reaction mixture was left under a magnetic stirrer
overnight until TLC showed the completion of the reaction.
MeOH was evaporated under reduced pressure using a rotary
evaporator, and H2O (30 mL) was added to the residue. Citric
acid (1 M aqueous solution) was added until acidic pH was
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reached. The aqueous layer was then extracted with EtOAc (2
× 50 mL). The combined organic layers were dried over
MgSO4 and concentrated under reduced pressure using a rotary
evaporator, giving pure PBD protected acid core 9 (3.2 g, 87%)
as a light yellow solid (mp 72 °C).
Rf value (DCM/acetone 60:40): 0.27;
1H NMR (400 MHz,
CDCl3) δ 7.20 (2 H, s), 6.89 (1 H, s), 6.58 (1 H, s), 5.87 (2 H,
d, J = 9.2 Hz), 5.72 (2 H, d, J = 9.2 Hz), 4.95−5.18 (5 H, m),
4.30−4.60 (5 H, m), 4.00−4.15 (7 H, m), 3.82−3.91 (7 H, m),
3.42−3.69 (9 H, m), 2.49−2.60 (4 H, m), 1.90−2.20 (12 H,
m), 1.67−1.81 (4 H, m), 1.40−1.60 (8 H, m). 13C NMR (100
MHz, CDCl3) δ 177.6, 167.6, 149.8, 132.1, 131.9, 126.7, 117.3,
114.9, 110.8, 100.7, 96.0, 91.7, 88.5, 67.9, 66.6, 63.6, 60.1, 56.1,
46.5, 31.1, 30.3, 28.8, 25.2, 24.1, 23.2, 20.0. m/z (+ESI) calc. for
C26H34N2O9 (M)
+ 518.5, found 519.2 ([M] + H)+.
4-(Benzyloxy)-3-methoxybenzaldehyde (10). Benzyl bro-
mide (12.9 mL, 108.4 mmol, 1.1 equiv) and potassium
carbonate (6.8 g, 49.3 mmol, 0.5 equiv) were added to a
solution of vanillin (15.0 g, 98.6 mmol, 1.0 equiv) in acetone
(225 mL). The suspension was stirred under reﬂux overnight
until TLC showed the completion of the reaction. At that
point, H2O (5000 mL) was added to the reaction, causing the
formation of a precipitate that was ﬁltered and recrystallized
from EtOH at 0 °C giving pure 10 (14.9 g, 62%) as a pale
yellow solid (mp 61 °C).
Rf value (100% DCM): 0.71;
1H NMR (400 MHz, CDCl3) δ
9.83 (1H, s), 7.29−7.46 (7H, m), 6.98 (1H, d, J = 8.06 Hz),
5.25 (2H, s), 3.94 (3H, s). 13C NMR (100 MHz, CDCl3) δ
191.0, 153.6, 150.1, 136.0, 130.3, 128.7, 128.2, 127.2, 126.6,
112.3, 109.3, 70.9, 56.1. m/z (+ESI) calc. for C15H14O3 (M)
+
242.3, found 242.9 ([M] + H)+.
4-(Benzyloxy)-5-methoxy-2-nitrobenzaldehyde (11). A sol-
ution of 10 (14.8 g, 61.1 mmol, 1.0 equiv) in triﬂuoroacetic acid
(18 mL) was added dropwise to a solution of KNO3 (7.7 g,
76.4 mmol, 1.25 equiv) in triﬂuoroacetic acid (18 mL) kept at 0
°C under a magnetic stirrer. After 40 min, the reaction went to
completion by TLC and LCMS. The reaction mixture was
evaporated under reduced pressure using a rotary evaporator.
The residue was dissolved in EtOAc (500 mL), and the organic
phase was washed with brine (3 × 500 mL). The organic
phases were dried over MgSO4 and concentrated by a rotary
evaporator giving pure 11 (14.5 g, 98%) as a bright yellow solid
(mp 114 °C).
Rf value (100% DCM): 0.73;
1H NMR (400 MHz, CDCl3) δ
10.42 (1H, s), 7.66 (1H, s), 7.34−7.46 (6H, m), 5.26 (2H, s),
4.0 (3H, s). 13C NMR (100 MHz, CDCl3) δ 187.8, 153.7,
151.4, 134.85, 129.0, 128.9, 128.7, 127.6, 125.7, 110.0, 108.9,
71.6, 56.7. m/z (+ESI) calc. for C15H13NO5 (M)
+ 287.3, found
285.9 ([M] − H)−.
4-Hydroxy-5-methoxy-2-nitrobenzaldehyde (12). A solu-
tion of 11 (14.4 g, 50.1 mmol, 1 equiv) in acetic acid (120 mL)
was heated up to 85 °C, and a hydrobromic acid solution (48%,
40 mL) was added. The mixture was kept under a magnetic
stirrer for 1 h. The solid product obtained was ﬁltered and
recrystallized from hot EtOH. The solid obtained was dried in a
vacuum oven giving pure 12 (6.1 g 62%) as a yellow solid (mp
212 °C).
Rf value (100% DCM): 0.51;
1H NMR (400 MHz, DMSO-
d) δ 11.12 (1H, br s), 10.16 (1H, s), 7.50 (1H, s), 7.35 (1H, s),
3.94 (3H, s). 13C NMR (100 MHz, DMSO-d) δ 188.3, 151.8,
151.0, 143.7, 123.4, 111.0, 110.6, 56.31. m/z (+ESI) calc.
C8H7NO5 (M)
+ 197.2, found 198.0 ([M] + H)+.
tert-Butyl (3-(4-Formyl-2-methoxy-5-nitrophenoxy)-
propyl)carbamate (13). tert-Butyl (3-bromopropyl)carbamate
(7.1 g, 29.6 mmol, 1.05 equiv) and potassium carbonate (5.8 g,
42.3 mmol, 1.5 equiv) were added to a solution of 12 (5.6 g,
28.2 mmol, 1.0 equiv) in DMF (22 mL). The suspension was
stirred at 50 °C for 24 h, until TLC showed the completion of
the reaction. At that point, H2O (500 mL) was added to the
reaction, and the product was extracted in EtOAc. The organic
solvent was then evaporated using the rotary evaporator, and
the compound was puriﬁed by ﬂash column chromatography
(mobile phase hexane/EtOAc, 80:20, v/v) to give pure 13 (9.3
g, 93%) as a brown oil.
Rf value (100% DCM): 0.68;
1H NMR (400 MHz, CDCl3) δ
10.44 (1H, s), 7.59 (1H, s), 7.41 (1H, s), 4.23 (2H, t, J = 5.92),
4.01 (3H, s), 3.34−3.43 (2H, m), 2.05−2.13 (2H, m), 1.45
(9H, s). 13C NMR (100 MHz, CDCl3) δ 188.5, 155.6, 152.6,
151.2, 143.5, 124.6, 110.0, 108.1, 77.6, 67.3, 56.4, 35.7, 28.8,
28.1. m/z (+ESI) calc. C16H22N2O7 (M)
+ 354.4, found 255.0
([M] + H-Boc)+, 377.0 ([M] + Na)+.
4-(3-((tert-Butoxycarbonyl)amino)propoxy)-5-methoxy-2-
nitrobenzoic acid (14). Compound 13 (9.2 g, 25.9 mmol, 1.0
equiv) was dissolved in acetone (500 mL). A hot solution of
10% potassium permanganate (250 mL) was added to the
solution of 13 in a ﬂask ﬁtted with a condenser. The reaction
mixture was left under reﬂux until the reaction went to
completion (according to TLC). At that point, the reaction
mixture was cooled down to room temperature. The brown
residue formed was ﬁltered through a Celite path and washed
with 600 mL of hot H2O. A solution of sodium bisulphite
(16%, 400 mL) was added to the ﬁltrate, and the pH of the
solution was adjusted to 3.5 using concentrated citric acid. The
product was then extracted in EtOAc. The organic solvent was
removed using the rotary evaporator, giving 14 (8.1 g, 83%) as
a yellow solid (mp 107 °C).
Rf value (EtOAc/MeOH 50:50): 0.57;
1H NMR (400 MHz,
CDCl3) δ 7.29 (1H, s), 7.08 (1H, br s), 4.10 (2H, t, J = 5.29
Hz), 3.89 (3H, s), 3.31−3.38 (2H, m), 2.02 (2H, quin, J = 5.79
Hz), 1.44 (9H, s). 13C NMR (100 MHz, CDCl3) δ 191.1,
156.2, 152.7, 149.0, 128.7, 127.2, 110.8, 107.6, 79.3, 68.3, 56.5,
38.4, 28.5, 28.4. m/z (+ESI) calc. C16H22N2O8 (M)
+ 370.4,
found 271.0 ([M] + H-Boc)+, 393.1 ([M] + Na)+.
tert-Butyl (S)-(3-(4-(2-(Hydroxymethyl)pyrrolidine-carbon-
yl)-2-methoxy-5-nitrophenoxy)propyl)carbamate (15). A sol-
ution was prepared by dissolving 14 (8.0 g, 21.6 mmol, 1.1
equiv), HBTU (18.6 g, 49.0 mmol, 2.5 equiv), and DIPEA
(10.2 mL, 58.8 mmol, 3 equiv) in DMF (250 mL). The
solution was left under a magnetic stirrer for 20 min. Then, (S)-
(+)-2-pyrrolidinemethanol (1.93 mL, 19.6 mmol, 1.0 equiv)
was added to the mixture which was kept under magnetic
stirring at 50 °C for 15 h until TLC showed the completion of
the reaction. At that point, water was added to the reaction
mixture, and the product was extracted in EtOAc. The organic
phase was then washed with brine and a saturated NaHCO3
solution. The organic solution was concentrated using a rotary
evaporator, and the product was puriﬁed by ﬂash column
chromatography (mobile phase: from 100% EtOAc to EtOAc/
MeOH, 98:2, v/v) to aﬀord pure 15 (3.2 g, 35%) as brown
solid (mp 68 °C).
Rf value (EtOAc/MeOH 90:10): 0.42;
1H NMR (400 MHz,
CDCl3) δ 7.67 (1H, s), 6.79 (1H, s), 4.16 (2H, t, J = 5.92 Hz),
3.97 (3H, s), 3.85−3.91 (1H, m), 3.75−3.82 (1H, m), 3.33−
3.40 (2H, m), 3.15 (2H, t, J = 6.55), 2.12−2.21 (2H, m), 2.03−
2.09 (2H, m), 1.68−1.93(4H, m), 1.44 (9H, s). 13C NMR (100
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MHz, CDCl3) δ 200.7, 156.0, 154.7, 153.2, 148.3, 127.9, 109.0,
108.0, 79.2, 68.4, 61.6, 56.7, 49.5, 38.5, 29.1, 28.5, 24.4. m/z
(+ESI) calc. C21H31N3O8 (M)
+ 453.5, found 454.1 ([M] + H)+.
tert-Butyl (S)-(3-(5-Amino-4-(2-(hydroxymethyl)-
pyrrolidine-1-carbonyl)-2-methoxyphenoxy)propyl)-
carbamate (16). A catalytic amount of Pd/C (10% w/w) was
added to a solution of 15 (3.2 g, 7.1 mmol, 1.0 equiv) in EtOH
(30 mL). The reaction mixture was hydrogenated in a Parr
hydrogenator at 40 psi overnight until TLC showed the
completion of the reaction. At that point, the reaction was
ﬁltered under vacuum through a path of Celite. The resulting
solution was evaporated using a rotary evaporator giving pure
16 (2.9 g, 96%) as a yellow solid (mp 73 °C).
Rf value (EtOAc/MeOH 90:10): 0.65;
1H NMR (400 MHz,
CDCl3) δ 6.72 (1H, s), 6.23 (1H, s), 4.04 (2H, t, J = 5.79 Hz),
3.79 (3H, s), 3.57−3.71 (2H, m), 3.51 (2H, td, J = 10.13, 6.42
Hz), 3.30−3.39 (2H, m), 2.10−2.20 (1H, m), 2.00 (2H, quin, J
= 5.85 Hz), 1.58−1.93 (4H, m), 1.45 (9H, s). 13C NMR (100
MHz, (CD3)2SO) δ 170.3, 168.5, 155.6, 150.1, 140.0, 112.9,
101.6, 101.2, 77.5, 65.8, 61.4, 61.4, 58.5, 56.4, 37.2, 29.1, 28.2,
27.1, 20.7. m/z (+ESI) calc. C21H33N3O6 (M)
+ 423.5, found
424.1 ([M] + H).
tert-Butyl (S)-(3-(5-(((Allyloxy)carbonyl)amino)-4-(2-
( h y d r o x ym e t h y l ) p y r r o l i d i n e - 1 - c a r b o n y l ) - 2 -
methoxyphenoxy)propyl)carbamate (17). A solution was
prepared by dissolving 16 (2.8 g, 6.6 mmol, 1.0 equiv) in dry
DCM (82 mL). Dry pyridine (1.42 mL) and a solution of allyl
chloroformate (0.67 mL, 6.3 mmol, 0.95 equiv) in anhydrous
DCM (57.38 mL) were sequentially added to this solution,
which was kept at −10 °C under an N2 atmosphere. The
reaction mixture was left under a magnetic stirrer at room
temperature for 2 h, until TLC showed the completion of the
reaction. At that point, the reaction mixture was extracted with
a saturated CuSO4 solution (100 mL), saturated aqueous
NaHCO3 (200 mL), and brine (200 mL). The organic phase
was dried over MgSO4 and concentrated under reduced
pressure using a rotary evaporator. Pure 17 (3.1 g, 94%) was
obtained as a brown solid (mp 47 °C).
Rf value (EtOAc/MeOH 90:10): 0.54;
1H NMR (400 MHz,
CDCl3) δ 7.73 (1H, dr s), 6.80 (1H, s), 5.87−6.01 (1H, m),
5.34 (1H, dd, J = 17.37,1.51 Hz), 5.23 (1H, dd, J = 10.32, 1.26
Hz), 4.62 (2H, dq, J = 5.70, 1.46 Hz), 4.13 (2H, t, J = 5.67 Hz),
3.83 (3H, s), 3.39−3.75 (4H, m), 3.34 (2H, q, J = 5.71), 2.10−
2.20 (1H, m), 2.01 (2H, quin, J = 5.85 HZ), 1.86−1.91 (2H,
m), 1.60−1.79 (2H, m), 1.44 (9H, s). 13C NMR (100 MHz,
CDCl3) δ 170.9, 156.1, 153.7, 150.3, 144.0, 132.5, 131.8, 118.2,
110.9, 105.4, 78.9, 68.0, 66.5, 65.8, 61.1, 56.3, 51.6, 38.8, 29.1,
28.5, 28.3, 25.15. m/z (+ESI) calc. C25H37N3O8 (M)
+ 507.6,
found 508.2 ([M] + H)+.
Allyl-8(3-((tert-butoycarbonyl)amino)propoxy)-11-hy-
droxy-7-methoxy-5-oxo-2,3,11,11a-tetrahydro-1H-benzo[e]-
pyrrolo[1,2-α][1,4]diazepine-10-(5H)carboxylate (18). BAIB
(2.4 g, 7.4 mmol, 1.2 equiv) and TEMPO (0.1 g, 0.6 mmol, 0.1
equiv) were sequentially added to a solution of 17 (3.14 g, 6.2
mmol, 1 equiv) in DCM (160 mL). The reaction was stirred for
6 h until TLC showed the completion of the reaction. At that
point, the reaction mixture was sequentially washed with
saturated sodium metabisulphite (100 mL), saturated aqueous
NaHCO3 (2 × 100 mL), and brine (100 mL). The organic
phase was dried over MgSO4 and concentrated under reduced
pressure using a rotary evaporator. The crude of the reaction
was puriﬁed by column chromatography (mobile phase:
EtOAc/DCM, 50/50, v/v) aﬀording pure 18 (3 g, 96%) as
an ochre solid (mp 75 °C).
Rf value (EtOAc/MeOH 90:10): 0.48;
1H NMR (400 MHz,
CDCl3) δ 7.22 (1H, s), 6.65 (1H, s), 5.69−5.84 (1H, m),
5.57−5.65 (1H, m), 5.46 (1H, br s), 4.64 (1H, dd, J = 13.35,
5.04 Hz), 4.42 (1H, dd, 13.35, 4.28 Hz), 4.01−4.07 (2H, m),
3.90 (3H, s), 3.64−3.71 (1H, m), 3.41−3.57 (2H, m), 3.32
(2H, d, J = 5,29 Hz), 2.06−2.13 (2H, m), 1.87−2.02 (5H,m),
1.43 (9H, s). 13C NMR (100 MHz, CDCl3) δ 166.9, 156.1,
155.9, 149.8, 148.6, 131.8, 128.4, 126.1, 118.0, 113.7, 110.5,
86.0, 79.0, 68.2, 66.7, 60.0, 56.0, 53.5, 46.4, 38.8, 29.1, 28.7,
28.5, 23.0. m/z (+ESI) calc. C25H35N3O8 (M)
+ 505.6, found
506.2 ([M] + H)+.
General Procedure Adopted for Amide Coupling Reac-
tions of the Biaryl Moieties (19−24). DMAP (3 equiv) and
EDCI (2 equiv) were added to a solution of carboxylic acid in
DMF (6 mL). The mixture was kept under N2 atmosphere and
magnetic stirring for 30 min. Subsequently, the amino
compound (1.5 equiv) was added to the solution, which was
left under a magnetic stirrer at room temperature overnight. An
aqueous solution of citric acid at pH = 2.5 (40 mL) was added
to the mixture, and the product was extracted with EtOAc. The
organic phase was washed with brine and concentrated using a
rotary evaporator. The crude product was puriﬁed by ﬂash
column chromatography (mobile phase: from DCM, 100%, to
DCM/acetone, 70/30, v/v.
tert-Butyl (5-(Benzofuran-5-ylcarbamoyl)-1methyl-1H-pyr-
rol-3-yl)carbamate (19). The reaction aﬀorded 330.0 mg
(67%) as pale brown solid (mp 176 °C).
Rf value (DCM/acetone 80:20): 0.71;
1H NMR (400 MHz,
CDCl3) δ 7.89 (1H, d, J = 1.51 Hz), 7.81 (1H, br s), 7.58 (1H,
d, J = 2.27 Hz), 7.39 (1H, d, J = 8.56 Hz), 7.24 (1H, d, J = 8.5 6
Hz), 6.83 (1H, s), 6.68 (1H, dd, J = 2.14, 0.88 Hz), 6.63 (1H,
s), 6.47 (1H, s), 3.85 (3H, s), 1.49 (9H, s). 13C NMR (100
MHz, CDCl3) δ 160.0, 153.6, 151.8, 145.8, 133.0, 127.8, 123.5,
121.8, 118.7, 117.9, 113.2, 111.4, 106.8, 103.9, 80.3, 36.7, 28.4.
m/z (+ESI) calc. for C19H21N3O4 (M)
+ 355.4, found 355.8
([M] + H)+.
N-(Benzofuran-5-yl)-4-cyano-1-methyl-1H-pyrrole-2-car-
boxamide (20). The reaction aﬀorded 429.0 mg (79%) as
yellow solid (mp 172 °C).
Rf value (DCM/acetone 80:20): 0.69;
1H NMR (400 MHz,
CDCl3) δ 7.92 (1H, d, J = 2.27 Hz), 7.80 (1H, s), 7.64 (1H, d, J
= 2.01 Hz), 7.48 (1H, d, J = 8.81), 7.31 (1H, dd, J = 8.69, 2.14
Hz), 7.24 (1H, d, J = 1.76 Hz), 6.99 (1H, d, J = 1.51 Hz), 6.76
(1H, dd, J = 2.27, 1.01 Hz), 4.01 (3H, s). 13C NMR (100 MHz,
CDCl3) δ 158.6, 152.2, 146.1, 133.6, 132.3, 128.0, 127.5, 118.0,
115.6, 114.7, 113.5, 111,7, 106.8, 92.1, 37.7. m/z (+ESI) calc.
for C15H11N3O2 (M)
− 265.3, found 263.9 ([M] − H)−.
Methyl 4-(Benzofuran-5-carboxamido)-1-methyl-1H-pyr-
role-2-carboxylate (21). The reaction aﬀorded 144.0 mg
(20%) as dark yellow solid (mp 163 °C).
Rf value (DCM/acetone 80:20): 0.63;
1H NMR (400 MHz,
CDCl3) δ 8.12 (1H, d, J = 1.51 Hz), 7.89 (1H, s), 7.79 (1H, dd,
J = 8.69, 1.64 Hz), 7.70 (1H, d, J = 2.27 Hz), 7.55 (2H, dd, J =
4.91, 3.15 Hz), 6.83 (1H, d, J = 2.27 Hz), 6.80 (1H, d, J = 1.76
Hz), 3.91 (3H, s), 3.81 (3H, s). 13C NMR (100 MHz, CDCl3)
δ 165.0, 161.5, 156.6, 146.4, 129.5, 127.7, 123.4, 121.9, 121.4,
120.7, 119.8, 111.6, 108.2, 107.0, 51.2, 36.9. m/z (+ESI) calc.
for C16H14N2O4 (M)
+ 298.3, found 299.1 ([M] + H)+.
tert-Butyl (5-(Benzo[b]thiophene-5-ylcarbamoyl)-1-meth-
yl-1H-pyrrol-3-yl)carbamate (22). The reaction aﬀorded 435.0
mg (93%) as brown solid (mp 164 °C).
ACS Infectious Diseases Article
DOI: 10.1021/acsinfecdis.7b00130
ACS Infect. Dis. XXXX, XXX, XXX−XXX
L
Rf value (DCM/acetone 80:20): 0.7;
1H NMR (400 MHz,
CDCl3) δ 8.21 (1H, d, J = 2.01 Hz), 7.80 (1H, d, J = 8.81), 7.70
(1H, s), 7.45 (1H, d, J = 5.29 Hz), 7.35 (1H, dd, J = 8.81, 2.01
Hz), 7.29 (1H, d, J = 5.54 Hz), 6.86 (1H, s), 6.67 (1H, s), 6.29
(1H, br s), 3.92 (3H, s), 1.51 (9H, s). 13C NMR (100 MHz,
CDCl3) δ 159.7, 153.5, 140.3, 135.3, 134.7, 127.5, 124.0, 123.5,
122.7, 121.8, 118.7, 117.7, 114.6, 103.8, 80.4, 36.8, 28.4. m/z
(+ESI) calc. for C19H21N3O3S (M)
+ 371.5, found 372.0 ([M] +
H)+.
N-(Benzo[b]thiophene-5-yl)-4-cyano-1-methyl-1H-pyrrole-
2-carboxamide (23). The reaction aﬀorded 970.3 mg (92%) as
brown solid (mp 173 °C).
Rf value (DCM/acetone 80:20): 0.66;
1H NMR (400 MHz,
CDCl3) δ 8.20 (1H, d, J = 2.01 Hz), 7.39 (1H, br s), 7.83 (1H,
d, J = 8.56 Hz), 7.48 (1H, d, J = 5.54 Hz), 7.39 (1H, dd, J =
8.69, 2.14 Hz), 7.30 (1H, d, J = 5.29 Hz), 7.24 (1H, d, J = 1.74
Hz), 7.02 (1H, d, J = 1.51 Hz), 4.01 (3H, s). 13C NMR (100
MHz, CDCl3) δ 158.6, 140.2, 136.0, 134.1, 133.7, 127.8, 127.4,
123.9, 122.9, 117.9, 115.5, 115.1, 114.8, 92.1, 37.7. m/z (+ESI)
calc. for C15H11N3OS (M)
− 281.3, found 281.9 ([M] + H)+.
Methyl (4-Benzo[b]thiophene-5-carboxamido)-1-methyl-
1H-pyrrole-2-carboxylate (24). The reaction aﬀorded 390.0
mg (88%) as white solid (mp 214 °C).
Rf value (DCM/acetone 80:20): 0.65;
1H NMR (400 MHz,
CDCl3) δ 8.28−8.30 (2H, m), 7.84−7.89 (1H, m), 7.77 (1H,
dd, J = 8.56, 1.76 Hz), 7.52 (1H, d, J = 2.01 Hz), 7.49 (1H, d, J
= 5.54 Hz), 7.32 (1H, d, J = 5.29 Hz), 6.83 (1H, d, J = 2.01
Hz), 3.86 (3H, s), 3.78 (3H, s). 13C NMR (100 MHz, CDCl3)
δ 165.0, 161.5, 142.8, 139.5, 130.6, 128.0, 124.2, 122.7, 122.6,
122.34, 121.9, 121.4, 119.9, 108.4, 51.2, 36.9. m/z (+ESI) calc.
for C16H14N2O3S (M)
+ 314.4, found 314.9 ([M] + H)+.
General Procedure Adopted for the Nitrile Hydrolysis (25,
26). The biaryl compound bearing the nitrile group was
solubilized in a mixture of dioxane (4 mL) and water (10 mL),
and concentrated H2SO4 (2 mL) was added to this mixture.
The solution was kept under magnetic stirring at 80 °C for 96
h. A saturated solution of NaHCO3 was slowly added until the
mixture reached pH = 8, and then, it was washed with EtOAc
(250 mL). The concentrated HCl was added to the aqueous
phase to reach pH = 2, and the product was extracted with
EtOAc (300 mL). The organic phase was concentrated using a
rotary evaporator, and the crude product was puriﬁed by ﬂash
column chromatography (mobile phase: from 100% EtOAc to
EtOAc/MeOH, 95/5, v/v).
5-(Benzofuran-5-ylcarbamoyl)-1-methyl-1H-pyrrole-3-car-
boxylic acid (25). The reaction aﬀorded 39.0 mg (9%) as
brown solid (186 °C).
Rf value (acetone/DCM 80:20): 0.37;
1H NMR (400 MHz,
(CD3)2SO) δ 10.03 (1H, s), 8.09 (1H, d, J = 1.51 Hz), 7.69
(1H, d, J = 2.01 Hz), 7.51−7.56 (3H, m), 7.37 (1H, d, J = 1.76
Hz), 6.95 (1H, d, J = 1.51 Hz), 3.88 (3H, s). 13C NMR (100
MHz, CH3OD-d) δ 162.0, 153.5, 147.3, 134.7, 134.0, 129.1,
128.4, 120.0, 116.0, 115.7, 115.1, 112.0, 107.8. m/z (+ESI) calc.
for C15H12N2O4 (M)
− 284.3, found 283.0 ([M] − H)−.
5-(Benzo[b]thiophene-5-ylcarbamoyl)-1-methyl-1H-pyr-
role-3-carboxylic acid (26). The reaction aﬀorded 85.0 mg
(7%) as brown solid (181 °C).
Rf value (acetone/DCM 80:20): 0.39;
1H NMR (400 MHz,
CD3OD-d) δ 8.20 (1H, d, J = 1.76 Hz), 7.85 (1H, d, J = 8.81
Hz), 7.52−7.59 (3H, m), 7.38 (1H, J = 1.76 Hz), 7.34 (1H, d, J
= 4.78 Hz), 3.99 (3H, s). 13C NMR (100 MHz, CD3OD-d) δ
141.6, 136.9, 136.5, 134.1, 128.5, 124.9, 123.4, 119.9, 116.6,
116.1, 115.8. m/z (+ESI) calc. for C15H12N2O3S (M)
− 300.3,
found 301.0 ([M] + H)+.
General Procedure Adopted for Boc-Deprotection (18, 19,
22). The Boc-protected compound was added to a mixture of
DCM (2 mL) and TFA (1 mL) and kept under a magnetic
stirrer for 30 min. The organic solvent was then evaporated
under vacuum.
General Procedure for Methyl Ester Hydrolysis (21, 24).
The compound bearing the methyl ester was solubilized in a
mixture of H2O (10 mL) and dioxane (2 mL), and an excess of
NaOH was added. The solution was kept under magnetic
stirring for 5 h until the completion of the reaction. The
dioxane was then eliminated under vacuum at the rotary
evaporator, and HCl was added to the aqueous solution to
reach pH = 2. The product was subsequently extracted with
EtOAc (50 mL), and the organic solvent was evaporated using
a rotary evaporator.
General Procedure Adopted for the Amide Coupling
between PBD Core and Biaryl Moiety and for the Final
Deprotection (27−32). The moiety bearing the carboxylic acid
was dissolved in DMF (4 mL), and DMAP (3 equiv) and EDCI
(2 equiv) were added to the solution, which was left under a
magnetic stirrer for 30 min. The amino compound was then
added to the mixture, which was kept in an N2 atmosphere and
was stirred at room temperature overnight at which point TLC
showed the completion of the reaction. Then, an aqueous
solution of citric acid (100 mL) at pH = 2 was added, and the
product was extracted with EtOAc (100 mL). The solvent was
evaporated under vacuum, and the product was puriﬁed by ﬂash
column chromatography (mobile phase: from DCM, 100%, to
DCM/acetone, 60:40, v/v). The compound obtained was
dissolved in DCM (3 mL), and Pd(PPh3)4 (0.05 equiv),
triphenylphosphine (0.25 equiv), and pyrrolidine (1.2 equiv)
were added. The solution was left under a magnetic stirrer for
30 min, and then, the solvent was evaporated using a rotary
evaporator. The obtained solid was kept under high vacuum for
15 min, and the product was ﬁnally puriﬁed through ﬂash
column chromatography (mobile phase: from DCM, 100%, to
DCM/acetone, 40:60, v/v).
(S)-N-(Benzofuran-5-yl)-4-(4-((7-methoxy-5-oxo-2,3,5,11a-
tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)-
butanamido)-1-methyl-1H-pyrrole-2-carboxamide (27). The
reaction aﬀorded 38.0 mg (38%) as white solid (mp 144 °C).
Rf value (DCM/acetone 20:80): 0.25;
1H NMR (400 MHz,
CDCl3) δ 8.19 (1H, s), 8.13 (1H, s), 7.92 (1H, d, J = 2.01 Hz),
7.62 (1H, d, J = 4.28 Hz), 7.57 (1H, d, J = 2.27 Hz), 7.47 (1H,
s), 7.31−7.41 (1H, m), 7.30 (1H, m), 7.09 (1H, d, J = 1.76
Hz), 6.68 (1H, dd, J = 2.14, 0,88 Hz), 6.57 (1H, d, J = 1.76
Hz), 4.05 (2H, t, J = 6.04 Hz), 3.85 (3H, s), 3.82 (3H, s),
3.72−3.79 (1H, m), 3.64−3.69 (1H, m), 3.50−3.54 (1H, m),
2.44−2.50 (2H, m), 2.16−2.33 (4H, m), 1.95−2.06 (3H, m).
13C NMR (100 MHz, CDCl3) δ 168.9, 163.6, 161.8, 159.0,
150.7, 149.6, 146.6, 144.7, 139.6, 132.2, 126.73, 122.2, 120.5,
119.3, 118.6, 117.0, 112.2, 110.6, 110.3, 109.7, 105.8, 103.0,
67.0, 55.0, 52.7, 45.7, 35.7, 29.9, 28.2, 23.9, 23.1. IR (FT/IR,
νmax/cm
−1): 1600, 1468, 1433, 1263, 1200, 1228, 760, 733.
HRMS (EI, m/z): calc for C31H31N5O6 (M), 570.2347; found,
570.2340.
(S)-N2-(benzofuran-5-yl)-N4-(3-((7-methoxy-5-oxo-
2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]-
diazepin-8-yl)oxy)propyl)-1-methyl-1H-pyrrole-2,4-dicarbox-
amide (28). The reaction aﬀorded 9.0 mg, (14%) as white solid
(mp 135 °C).
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Rf value (EtOAc/methanol 95:5): 0.23;
1H NMR (400 MHz,
CDCl3) δ 8.18 (1H, br s), 7.95 (1H, d, J = 1.51 Hz), 7.65 (1H,
d, 4.28 Hz), 7.61 (1H, d, J = 2.27 Hz), 7.52 (1H, s), 7.45 (1H,
d, J = 8.81 Hz), 7.34 (1H, dd, J = 8.31, 1.51 Hz), 7.29 (1H, s),
7.15 (1H, br s), 6.83 (1H, s), 6.79 (1H, br s), 6.75 (1H, d, J =
2.01 Hz), 4.21−4.29 (1H, m), 4.11−4.18 (1H, m), 3.98 (3H,
s), 3.86 (3H, s), 3.76−3.80 (1H, m), 3.53−3.72 (4H, m), 2.26−
2.33 (2H, m), 1.94−2.07 (4H, m). 13C NMR (100 MHz,
CDCl3) δ 163.9, 162.9, 159.7, 152.0, 150.5, 147.5, 145.9, 141.0,
132.9, 129.5, 127.9, 126.7, 120.6, 118.7, 117.9, 113.2, 112.3,
111.6, 111.0, 110.5, 106.9, 68.7, 56.4, 53.8, 53.7, 46.7, 37.3,
29.6, 29.3, 24.2. IR (FT/IR, νmax/cm
−1): 1572, 1263, 1215,
1200, 1084, 1026, 760, 623. HRMS (EI, m/z): calc for
C31H31N5O6 (M), 570.2347; found, 570.2344.
(S)-4-(Benzofuran-5-carboxamido)-N-(3-((7-methoxy-5-
oxo-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]-
diazepin-8-yl)oxy)propyl)-1-methyl-1H-pyrrole-2-carboxa-
mide (29). The reaction aﬀorded 20.0 mg (22%) as white solid
(mp 139 °C).
Rf value (DCM/acetone 20:80): 0.26;
1H NMR (400 MHz,
CDCl3) δ 8.71 (1H, s), 8.19 (1H, d, J = 1.76 Hz), 7.87 (1H, dd,
J = 8.81, 1.76 Hz), 7.66 (1H, d, 2.27 Hz), 7.63 (1H, d, J = 4.53
Hz), 7.51 (1H, d, J = 8.56 Hz), 7.44 (1H, s), 7.35 (1H, d, J =
1.76 Hz), 6.79 (1H, dd, J = 2.27, 0.76 Hz), 6.72−6.77 (2H, m),
6.52 (1H, d, J = 1.76 Hz), 4.16−4.23 (1H, m), 4.06−4.10 (1H,
m), 3.86 (3H, s), 3.74−3.82 (4H, m), 3.60−3.68 (2H, M),
3.49−3.56 (2H, m), 2.24−2.32 (2H, m), 1.99−2.10 (4H, m).
13C NMR (100 MHz, CDCl3) δ 165.0, 164.6, 162.6, 161.8,
156.5, 150.4, 147.6, 146.3, 140.6, 129.6, 127.6, 123.7, 123.5,
121.7, 120.9, 120.4, 119.3, 111.4, 110.4, 107.1, 103.6, 68.4, 55.9,
53.8, 46.7, 37.4, 36.5, 29.6, 29.3, 24.2. IR (FT/IR, νmax/cm
−1):
1599, 1433, 1410, 1265, 1198, 1142, 812, 731, 623. HRMS (EI,
m/z): calc for C31H31N5O6 (M), 570.2347; found, 570.2344.
(S)-N-(Benzo[b]thiophen-5-yl)-4-(4-((7-methoxy-5-oxo-
2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]-
diazepin-8-yl)oxy)butanamido)-1-methyl-1H-pyrrole-2-car-
boxamide (30). The reaction aﬀorded 60.0 mg (57%) as white
solid (mp 139 °C).
Rf value (DCM/acetone 20:80): 0.28;
1H NMR (400 MHz,
(CD3)2SO) δ 9.93 (2H, d, J = 2.27 Hz), 8.35 (1H, d, J = 2.01
Hz), 7.90 (1H, d, J = 8.81 Hz), 7.78 (1H, d, J = 4.28 Hz), 7.74
(1H, d, J = 5.54 Hz), 7.63 (1H, dd, J = 8.69, 1.89 Hz), 7.42
(1H, d, J = 5.29 Hz), 7.33 (1H, s), 7.24 (1H, d, J = 1.76 Hz),
7.00 (1H, d, J = 1.76 Hz), 6.83 (1H, s),4.09−4.18 (1H, m),
3.99−4.08 (1H, m), 3.85 (3H, s), 3.83 (3H, s), 3.56−3.42 (1H,
m), 2.45 (2H, t, J = 7.43 Hz), 2.14−2.31 (2H, m), 2.00−2.08
(2H, m), 1.87−1.96 (2H, m). 13C NMR (100 MHz,
(CD3)2SO) δ 168.8, 164.2, 163.3, 159.8, 150.1, 146.9, 140.5,
139.7, 136.2, 133.6, 127.9, 124.0, 122.6, 122.3, 122.0, 119.8,
118.8, 118.2, 114.4, 111.1, 110.0, 104.8, 67.7, 55.5, 53.4, 46.3,
36.2, 31.9, 28.8, 24.7, 23.6. IR (FT/IR, νmax/cm
−1): 1620, 1595,
1261, 1198, 1157, 1020, 874, 768, 692, 581. HRMS (EI, m/z):
calcd for C31H31N5O5S1 (M), 586.2119; found, 586.2114.
(S)-N2-(Benzo[b]thiophen-5-yl)-N4-(3-((7-methoxy-5-oxo-
2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]-
diazepin-8-yl)oxy)propyl)-1-methyl-1H-pyrrole-2,4-dicarbox-
amide (31). The reaction aﬀorded 8.5 mg (14%) as a pale
yellow solid (mp 142 °C).
Rf value (DCM/acetone 20:80): 0.26;
1H NMR (400 MHz,
CDCl3) δ 8.26 (1H, br s), 8.24 (1H, s), 7.80 (2H, dd, J = 8.44,
5.41 Hz), 7.65 (1H, d, J = 3.53 Hz), 7.52 (1H, s), 7.40−7.47
(2H, m), 7.35 (1H, d, J = 8.06 Hz), 7.29 (1H, s), 7.19 (1H, s),
6.82 (1H, dr.s), 4.21−4.30 (1H, m), 4.08−4.18 (1H, m), 3.98
(3H, s), 3.86 (3H, s), 3.75−3.82 (2H, m), 3.51−3.69 (4H, m),
2.25−2.34 (2H, m), 1.93−2.09 (4H, m). 13C NMR (100 MHz,
CDCl3) δ 163.9, 162.8, 160.7, 159.7, 152.0, 147.5, 140.2, 135.5,
129.9, 129.6, 128.1, 127.6, 126.6, 124.0, 122.8, 117.9, 114.8,
112.4, 111.2, 68.7, 56.4, 53.7, 46.7, 37.4, 31.8, 29.7, 29.3, 24.2,
21.7. IR (FT/IR, νmax/cm
−1): 1599, 1572, 1431, 1024, 970, 808,
768, 694, 482. HRMS (EI, m/z): calc for C31H31N5O5S1 (M),
586.2119; found, 586.2116
(S)-4-(Benzo[b]thiophene-5-carboxamido)-N-(3-((7-me-
thoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-
a][1,4]diazepin-8-yl)oxy)propyl)-1-methyl-1H-pyrrole-2-car-
boxamide (32). The reaction aﬀorded 57.0 mg (36%) as pale
yellow solid (mp 169 °C).
Rf value (DCM/acetone 20:80): 0.28;
1H NMR (400 MHz,
CDCl3) δ 9.27 (1H, s), 8.40 (1H, s), 7.86−7.91 (1H, m),
7.81−7.85 (1H, m), 7.58 (1H, d, J = 4.28 Hz), 7.44 (1H, d, J =
5.54 Hz), 7.38 (1H, s), 7.33 (1H, d, J = 1.76 Hz), 7.28 (1H, d, J
= 5.54 Hz), 6.79 (1H, t, J = 5.54 Hz), 6.70 (1H, s), 6.56 (1H, d,
J = 1.76 Hz), 4.05−4.13 (1H, m), 3,94−4.02 (1H, m), 3.78
(3H, s), 3.71 (3H, s), 3.41−3.65 (5H, m), 2,23 (2H, t, J = 6.29
Hz), 1.90−2.02 (4H, m). 13C NMR (100 MHz, CDCl3) δ
165.0, 164.7, 162.5, 161.8, 150.4, 147.5, 142.5, 140.5, 139.4,
130.7, 127.7, 124.3, 123.5, 123.0, 122.9, 122.4, 121.9, 120.2,
119.3, 111.3, 110.2, 103.8, 68.3, 55.9, 53.7, 46.7, 37.3, 36.4,
29.5, 29.3, 24.2. IR (FT/IR, νmax/cm
−1): 1600, 1431, 1261,
1200, 1161, 869, 810, 694, 606, 482. HRMS (EI, m/z): calc for
C31H31N5O5S1 (M), 586.2119; found, 586.2113.
FRET Based DNA Melting Assay. The oligonucleotide
sequence used for the FRET based DNA thermal denaturation
assays was purchased from Eurogentec, Southampton, UK.
Netropsin hydrochloride was purchased from Sigma-Aldrich
UK. The working solution of the oligonucleotide solution (400
nM) was prepared in a FRET buﬀer (optimized as 50 mM
potassium, 50 mM cacodylate, pH 7.4). The oligonucleotides
were annealed by heating the samples to 85 °C for 6 min
followed by cooling to 25 °C and storing at this temperature for
5 h. Annealed DNA (25 μL) and sample solution (25 μL) were
added to each well of a 96-well plate (MJ Research, Waltham,
MA), incubated for 3 h, and processed in a DNA Engine
Opticon (MJ Research). Fluorescence readings were taken at
intervals of 0.5 °C over the range of 30−100 °C, with a
constant temperature maintained for 30 s prior to each reading.
The raw data was imported into the Origin program (Version
7.0, OriginLab Corp.), and the graphs were smoothed using a
10-point running average and then normalized. The determi-
nation of melting temperatures was based on values at the
maxima of the ﬁrst derivative of the smoothed melting curves
using a script. The diﬀerence between the melting temperature
of each sample and that of the blank (ΔTm) was used for
comparative purposes.
Eukaryotic Toxicity Determination. Cell Culture. The
HeLa (human cervical cancer) cell line was obtained from the
American Type Culture Collection. The HeLa cell line was
maintained in Dulbecco’s Modiﬁed Eagles Media (DMEM;
Invitrogen) supplemented with fetal bovine serum (10% v/v;
Invitrogen), L-glutamine (2 mM; Invitrogen), nonessential
amino acids (1×; Invitrogen), and penicillin−streptomycin (1%
v/v, Invitrogen). For WI-38, high glucose DMEM (4.5 g/L;
Invitrogen), fetal bovine serum (10%, Biosera UK), non-
essential amino acids (1×; Invitrogen), and L-glutamine (2
mM; Invitrogen) were used for subculturing. During seeding,
cells were counted using a Neubauer hemocytometer
(Assistant, Germany) by microscopy (Nikon, USA) on a
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nonadherent suspension of cells that were washed in PBS,
trypsinized, centrifuged at 8 °C at 8000 rpm for 5 min, and
resuspended in a fresh medium.
MTT Assay. The cells were grown in normal cell culture
conditions at 37 °C in a 5% CO2 humidiﬁed atmosphere using
the cell-speciﬁc medium listed in the cell culture section above.
The cell count was adjusted to 105 cells/mL, and 10 000 cells
were added per well. The cells were incubated for 24 h, and 1
μL of the appropriate ligand concentration was added to the
wells in triplicate. After 24 h of continuous exposure to each
compound, the cell viability was determined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(Lancaster Synthesis Ltd., UK) colorimetric assay. Absorbance
was quantiﬁed by spectrophotometry at λ = 570 nm (Envision
Plate Reader, PerkinElmer, USA). Percentage survival values
were calculated by a dose−response analysis using the
GraphPad Prism software.
Microbiological Evaluation. Minimum Inhibitory Con-
centration (MIC). The MIC is the lowest concentration of an
antimicrobial that will inhibit the growth of 99% of a
microorganism after overnight incubation. The MIC of the
synthesized compounds was determined using the broth
microdilution method. Bacteria were grown in Tryptic Soy
Broth (TSB) (Sigma) or on Tryptic Soy Agar (TSA) plates at
37 °C. A solution of 128 μg/mL of the synthesized molecules
in water was prepared from a 2 mg/mL stock solution in
DMSO and then sequentially diluted by 2-fold in a 96 well
plate. 100 μL of bacterially infected media at a concentration of
1× 106 CFU/mL was inoculated in each well (ﬁnal bacterial
conc. of 5 × 105 CFU/mL). The maximum DMSO content in
each well after the addition of the media was ≤1%. The plate
was then incubated statically at 37 °C for 20 h, and absorbance
at a wavelength of 600 nm (OD600) was measured.
Time-Kill Kinetics Assay. The bactericidal or bacteriostatic
mode of killing was analyzed using a time-kill assay. Brieﬂy, 10
mL of bacteria at a starting concentration of approximately 106
CFU/mL was incubated in a glass conical ﬂask in TSB for 24 h
at 37 °C with shaking in the presence of the compound at 4×
MIC. At speciﬁed time-points, 100 μL was removed from the
culture and diluted in PBS using the method of Miles et al.33 10
μL spots of the dilutions were plated onto TSA plates and
incubated overnight at 37 °C to obtain a cell count.
Gyrase Inhibition Assay. The wild-type gyrase and the
gyrase with the S84L mutation were treated with compound 29
and the positive control ciproﬂoxacin using the cell-free
S. aureus gyrase supercoiling high throughput plate assay
(#SATRG01), obtained from Inspiralis (Norwich, UK).34 This
assay is based on the fact that negatively supercoiled plasmids
form intermolecular triplex DNA more readily than relaxed
plasmids under the experimental condition. The methods were
conducted as per the manufacturer’s instructions as described
previously.35 Brieﬂy, a relaxed pNO1, a modiﬁed form of
pBR322 which contains a “triplex-forming sequence”, was used
as the substrate. Initially, the wells were hydrated using 1×
wash buﬀer (20 mM Tris·HCl (pH 7.6), 137 mM NaCl,
0.005% (w/v) bovine serum albumin (acetylated), 0.05% (v/v)
Tween-20). This was followed by immobilization of 100 μL of
500 nM TFO1 oligo in each well by incubating for 5 min at
room temperature. Excess oligo was carefully washed with assay
buﬀer and ultrapure water. Twenty-four μL of mix buﬀer was
prepared by adding 0.75 μL of pNO1, 6 μL of assay buﬀer (40
mM HEPES, KOH, 10 mM magnesium acetate, 10 mM DTT,
2 mM ATP, 500 mM potassium glutamate, 0.05 mg/mL
albumin, pH 7.6), and 17.25 μL of ultrapure water. The mix
buﬀer was added to each well. This was followed by addition of
3 μL of inhibitor and 3 μL of dilution buﬀer (50 mM Tris·HCl,
1 mM DTT, 1 mM EDTA, 40% (w/v) glycerol). The plate was
incubated at 37 °C for 30 min. This was followed by the
addition of 100 μL of TF (triplex forming) assay buﬀer (10
mM sodium acetate, pH 4.7, 50 mM sodium chloride, and 50
mM magnesium chloride) and incubating the plate for a further
period of 30 min to allow triplex formation. The wells were
washed with 200 μL of TF buﬀer to remove the unbound
plasmid. Finally, PR omega diamond dye (in 10 mM Tris-HCl,
pH 8, 1 mM EDTA) was added, and the plates were read by a
ﬂuorescent plate reader (ex. 495−15, em. 537−20) after 20 min
of incubation at room temperature in the dark.
Molecular Modeling. Preparation of DNA and Com-
pounds Structures. Double strand (DS) DNA type B (BDNA)
was generated by the NAB module of the AMBER 12.0 package
program, using the template of the sequences used in the study
(AT-rich 5′-TATATAAGATATATATA-3′, mixed 5′-TAG-
CTAGCTAGCTAGCG-3′, and GC-rich 5′-GCGCGCGC-
GCGGCGCGC-3′). PDB ﬁles for the ligands were generated
by Chem3DPro 13.0. DNA and compounds’ structures were
minimized by SYBYL software before covalent molecular
docking.
Covalent Molecular Docking. Covalent docking was
performed by forming the covalent bond between the exocyclic
amine of guanine and the N10−C11 imine of the PBD using
the Autodock SMINA.36 C11-S-stereochemistry was main-
tained in every case at the binding interface of the PBD. All
parameters were kept at their default values.
Molecular Dynamics (MD) Simulations. After covalent
molecular docking, the best poses of each complex were
selected as the starting structures to run MD simulations for 10
ns. The MD simulations were carried out using the AMBER
12.0 package program. The force ﬁelds parameters for the
compounds were generated using the ANTECHAMBER
module of AMBER program. Each system was solvated by
using an octahedral box of TIP3P water molecules. Periodic
boundary conditions and the particle-mesh Ewald (PME)
method were employed in all the simulations.37 During each
simulation, all bonds in which the hydrogen atom was present
were considered ﬁxed, and all other bonds were constrained to
their equilibrium values by applying the SHAKE algorithm.38 A
cutoﬀ radius of 12 Å was used for the systems. Minimization
was performed in two phases, and each phase was performed in
two stages. In the ﬁrst phase, ions and all water molecules were
minimized for 500 cycles of the steepest descent followed by
500 cycles of conjugate gradient minimization. Afterward, the
whole systems were minimized for a total of 1000 cycles
without restraint wherein 500 cycles of steepest descent were
followed by 500 cycles of conjugate gradient minimization.
After minimizations, the systems were heated for 100 ps while
the temperature was raised from 0 to 300 K, and then,
equilibration was performed without a restraint for 100 ps while
the temperature was kept at 300 K. Sampling of reasonable
conﬁgurations was conducted by running a 10 ns simulation
with a 2 fs time step at 300 K and 1 atm pressure. A constant
temperature was maintained by applying the Langevin
algorithm while the pressure was controlled by the isotropic
position scaling protocol used in AMBER.39
MM-PBSA/MM_GBSA Calculation. Twenty snapshots were
collected from the last 200 ps of simulations of DNA−
compound complexes for postprocessing analysis. The ΔGPB
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term was calculated by solving the ﬁnite-diﬀerence Poisson−
Boltzmann equation using the internal PBSA program.40 The
SCALE value was set to 2. The Parse radii were employed for
all atoms. The solvent probe radius was set at 1.4 Å (with the
radii in the prmtop ﬁles). MM-PBSA running was performed
with the pbsa module (PROC = 2). The value of the exterior
dielectric constant was set at 80, and the solute dielectric
constant was set at 1.41 The nonpolar contribution was
determined on the basis of the solvent accessible surface area
(SASA) using the LCPO method42 and CAVITY-OFFSET set
at 0.00.
Molecular Docking of the Compounds to Wild and
Mutant Gyrase A. AutoDock SMINA was used for molecular
docking of ciproﬂoxacin, as a control, and compound 29 to the
minimized crystal structure of gyrase A from S. aureus (PDB ID
code 2XCT), for ﬁnding the best binding pocket by exploring
all probable binding cavities in the enzyme. All the parameters
were kept in their default values. Then, GOLD molecular
docking was used for molecular docking of the compounds into
the SMINA-located binding site for performing ﬂexible
molecular docking and determining more precise and evaluated
energies and scores. On the basis of the ﬁtness function score
and ligand binding position, the best-docked pose for each
compound was selected. The high ﬁtness function score,
generated using the GOLD program, with a low binding energy
value, reveals the best-docked pose for each system.
In this study, molecular docking of the compounds to the
mutant form of gyraseA was performed as well. After altering
Ser84 to Leu with a proper rotamer using PyMOL software, the
new structure of gyraseA_S84L was minimized by using Sybyl
program. For minimization, the method was set to Pawell,
initial optimization was set to Simplex, termination was set to
Gradient 0.01 kcal/(mol·A), and the maximum interactions
were set to 10 000. The minimized structure of the mutant
enzyme was used to run the molecular docking by GOLD, as
explained above, for the wild-type. A genetic algorithm (GA) is
used in GOLD ligand docking to thoroughly examine the
ligand conformational ﬂexibility along with the partial ﬂexibility
of the protein. The maximum number of runs was set to 20 for
each compound, and the default parameters were selected (100
for the population size, 5 for the number of islands, 100 000 for
the number of operations, and 2 for the niche size). Default
cutoﬀ values of 2.5 Å (dH-X) for hydrogen bonds and 4.0 Å for
van-der-Waals distance were employed. When the top solutions
attained the RMSD values within 1.5 Å, the GA docking was
terminated.
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